profit from every $100 of sales.
$0$100
Bruker
$60.33-3.33% today
+42.0% in 1 year
1-year low $32.761-year high $66.54
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Bruker sold, what it kept, and what it did with the cash.
Sales went from $2.53 billion in 2022 to $3.44 billion in 2025, with -$8.60 million of profit last year.
SalesProfit
Bruker handed back more cash to shareholders than it generated last year.
$33M
Free cash flow 2025$14M
Bought back its own shares$10M
Paid as dividends$33M
Cash vs. debt$299M vs. $2.0B
Bruker vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Bruker | No profit yet | ||
 Abbott Laboratories | 28.5× · Fair price | ||
 Medtronic | 26.9× · Fair price | ||
 Stryker | 36.6× · Expensive | ||
 Edwards Lifesciences | 56.7× · Expensive |
AI analysis
An AI analyst reads Bruker's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 1,988 | 2,418 | 2,531 | 2,965 | 3,366 | 3,437 | |
| 940 | 1,210 | 1,306 | 1,513 | 1,650 | 1,578 | |
| – | – | 462 | 489 | 379 | 236 | |
| 321 | 497 | 519 | 676 | 439 | 303 | |
| 158 | 277 | 297 | 427 | 113 | -9 | |
| 1.02 | 1.81 | 1.99 | 2.90 | 0.76 | -0.15 | |
| 47.3% | 50.0% | 51.6% | 51.0% | 49.0% | 45.9% | |
| – | – | 18.3% | 16.5% | 11.3% | 6.9% | |
| 7.9% | 11.5% | 11.7% | 14.4% | 3.4% | -0.3% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 3,049 | 3,650 | 3,612 | 4,250 | 5,807 | 6,241 |
| Cash | 682 | 1,068 | 646 | 488 | 183 | 299 |
| Total debt | 892 | 1,376 | 1,270 | 1,380 | 2,245 | 2,043 |
| Total liabilities | – | – | 2,480 | 2,837 | 3,992 | 3,731 |
| 961 | 1,071 | 1,114 | 1,377 | 1,781 | 2,457 | |
| 0 | 0 | 149 | 147 | 150 | 152 | |
| 10.2% | 13.2% | 14.2% | 16.1% | 5.0% | 1.4% | |
| 16.4% | 25.9% | 26.6% | 31.0% | 6.3% | -0.4% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 332 | 282 | 274 | 350 | 251 | 134 | |
| 97 | 92 | 129 | 107 | 115 | 120 | |
| 235 | 190 | 145 | 243 | 136 | 14 | |
| Dividends paid | 25 | 24 | 30 | 29 | 30 | 33 |
| 123 | 153 | 263 | 152 | 0 | 10 | |
| 16 | 17 | 28 | 31 | 25 | 20 |
Valuation
- –
- 28.5×
- –
- 4.1×
- 2.7×
- 662.9×
- 36.2×
- 0.2%
- -0.1%
- 0.4%
Profitability
- 45.9%
- 6.9%
- -0.3%
- 9.2%
- 1.5%
- 9.4%
- -0.5%
- -0.2%
- 4.3%
- 11.5%
Growth
- +11.6%
- –
- −68.2%
- +4.6%
- +0.5%
Financial health
- 5.8×
- 0.83
- 27.3%
- 1.4×
- 1.73
- 0.72
- 0.56
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 39%of 952
Bottom 44%of 883
Top 49%of 870
Bottom 41%of 985
What analysts expect
- Average price target
- $52.13
- Range
- $35.00 – $60.00
- 4 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 0.31 | 0.23 | +34.8% |
| Feb 12, 2026 | 0.59 | 0.65 | −9.2% |
| Nov 3, 2025 | 0.60 | 0.33 | +81.8% |
| Aug 4, 2025 | 0.32 | 0.33 | −3.0% |
| May 7, 2025 | 0.47 | 0.46 | +2.2% |
| Feb 13, 2025 | 0.76 | 0.75 | +1.3% |
| Nov 5, 2024 | 0.60 | 0.61 | −1.6% |
| Aug 6, 2024 | 0.52 | 0.52 | +0.0% |
0.4%of the share price, paid each year
On $1,000 invested$4a year at today's yield, before tax
+4.6%2020 to 2025
Raised–not every year
Paid per share, each year
$0.16 in 2016 → $0.20 in 2025
How safe it looks
-377.6% of its profit
Room to growStretchedMore than it earns: 236.7%
News
Bruker expects FY 2026 non-GAAP EPS of $2.10-$2.15 while targeting 250-300 bps operating margin expansionSeeking Alpha · Nov 4, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
17No pass
Benjamin Graham
24No pass
Philip Fisher
33No pass
Peter Lynch
46No pass
Joel Greenblatt
0No pass
Charlie Munger
24No pass
Terry Smith
21No pass
Questions about Bruker
Is Bruker a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Bruker AI analysis
What does Bruker do?
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It is in Medical Devices, based in Billerica, MA, United States, with 11,085 employees.
Does Bruker pay a dividend?
Yes. At today's price the dividend is 0.4% a year. In 2025 it paid out $32.9 million in dividends.
Is Bruker stock halal?
Yes. Bruker passes our halal screen: its business is permitted and its debt is 22% of its market value, under the 30% limit. How we check
How has Bruker stock done over the past year?
Up 42.0% over the past twelve months, to $60.33. It traded between $32.76 and $66.54 and is 9.3% below its high.
Who are Bruker's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with Bruker's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.